| Completed |
: Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
: - Cancer
- Chronic Myelomonocytic Leukemia
: 2008-06-27
: Drug: Clofarabine Clofarabine is a rationally designed, second generation purine nucleoside analogue. Cl
|
| Active, not recruiting |
: Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
: - Myelodysplastic Syndrome
- Leukemia, Myelomonocytic, Chronic
: 2014-03-07
: Other: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion As desc
|
| Completed |
: Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
: - Myelodysplastic Syndromes (MDS)
- Chronic Myelomonocytic Leukemia
: 2007-09-11
: - Drug: Subcutaneous (SC) Azacitidine
|
| Recruiting |
: Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
: - Myelodysplastic Syndromes
- Acute Myeloid Leukemia
-
: 2016-07-20
: Drug: H3B-8800 H3B-8800 capsules will be administered at assigned dose regimen (at the maximum tolerated
|
| Active, not recruiting |
: A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
: - Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
: 2009-07-07
: - Drug: Panobinostat (LBH589) and 5-Azacytidine
|
| Completed |
: Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
: - Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
: 2014-07-25
: - Drug: Azacitidine Azacitidine
|
| Recruiting |
: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
: - Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
<
: 2016-10-13
: - Drug: Atezolizumab Given IV
|
| Completed |
: A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
: - Myelodysplastic Syndromes (MDS)
- Chronic Myelomonocytic Leukemia
: 2012-05-24
: Drug: Panobinostat Other Name: LBH589
|
| Completed |
: A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
: - Myelofibrosis
- Myeloid Metaplasia
- Agnogenic Myeloid Metapla
: 2005-08-25
: Drug: Imatinib mesylate 400mg orally once daily until disease progression or unacceptable side effects
|
| Completed |
: Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
: Leukemia
: 2010-11-04
: - Drug: azacitidine
- Other: laboratory biomar
|
